Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. It offers medical care and supplemental benefit plans to individuals. The company also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, it provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; and military services, such as TRICARE T2017 East Region contract. Further, the company engages in the operation of pharmacy benefit manager business; operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. It sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Humana Inc.

Benchmark Co. analyst Bruce Jackson maintained a Buy rating on Humacyte yesterday and set a price target of $11.00. The company’s shares closed yes...

Benchmark Co. Keeps Their Buy Rating on Humacyte (HUMA)

Humm Group Limited ( ($AU:HUM) ) just unveiled an update. Humm Group Limited has announced the issuance of 7,025,995 ordinary fully paid shares to ...

Humm Group Issues Shares for Employee Incentive Plan

Humm Group Limited ( ($AU:HUM) ) has provided an update. Humm Group Limited has issued 7,025,995 fully paid ordinary shares to the trustee of its E...

Humm Group Enhances Employee Incentive Plan with New Share Issuance

An update from Humm Group Limited ( ($AU:HUM) ) is now available. At its 2025 Annual General Meeting, humm Group Limited announced the results of i...

humm Group Faces Shareholder Dissent at 2025 AGM

Humm Group Limited ( ($AU:HUM) ) has issued an update. Humm Group Limited received a non-binding indicative proposal from The Abercrombie Group Pty...

Humm Group Evaluates Acquisition Proposal Amidst Shareholder Scrutiny

An announcement from Humm Group Limited ( ($AU:HUM) ) is now available. Humm Group Limited’s FY25 results highlight a 10% increase in assets under ...

Humm Group Reports Strong FY25 Results with Strategic Investments

Shares of top health insurers, including Oscar Health ($OSCR), Elevance Health ($ELV), and Centene ($CNC), fell on Monday. The recent decline follo...

OSCR, ELV, CNC: Why Investors Are Selling Health-Insurance Stocks

In a report released yesterday, Sarah James from Cantor Fitzgerald maintained a Hold rating on Humana, with a price target of $290.00. James covers...

Cantor Fitzgerald Keeps Their Hold Rating on Humana (HUM)

Humm Group Limited ( ($AU:HUM) ) has provided an announcement. humm Group Limited announced the conclusion of discussions with The Abercrombie Grou...

humm Group Ends Acquisition Talks with The Abercrombie Group

An announcement from Humana AB ( ($SE:HUM) ) is now available. Humana AB has increased its holding of own shares to 2,611,036, representing 5% of t...

Current Quarter	$-3.93	Next Quarter	$10.23
Current Year	$17.08	Next Year	$12.68
QoQ Growth	+360.3%	YoY Growth	-25.8%
3Y EPS CAGR	N/A	Target Price	$285.50
Consensus	Buy	Upside	+25.7%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HUM	$227.10	+1.71%	1.78M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	HUM	$227.10	+1.7%	1.78M
3
4
5
6

HUM

HUM

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Humana Inc. Data in Excel

Get Humana Inc. Data in Excel